Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BlossomHill Therapeutics, Inc.BLSM · Entity 5423 | Director · President and CEO · 10% owner | August 06, 2026 | August 10, 2026 |
| Turning Point Therapeutics, Inc.TPTX · Entity 124461 | Director | June 09, 2020 | June 10, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BlossomHill Therapeutics, Inc.
Report date August 06, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Li and Cui Family Trust | 1,714,117 |
Last balance in matching sequence
After 2026-08-10 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-08-10 · Conversion · Acquired 1,600,682 · Balance 1,600,682 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. Row 2 · 2026-08-10 · Conversion · Acquired 113,435 · Balance 1,714,117 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy RongShan, LLC | 124,779 |
Reported balance
After 2026-08-10 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-08-10 · Conversion · Acquired 124,779 · Balance 124,779 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3: The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-08-05 | Direct | 676,205 |
Reported balance
After 2026-08-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-06 · Grant · Acquired 676,205 · Balance 676,205 F4: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months. |
| Series Angel Preferred StockSEC Table II · derivative / convertible security | IndirectBy The Li and Cui Family Trust | 0 |
Reported balance
After 2026-08-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-10 · Conversion · Disposed 1,600,682 · Balance 0 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy The Li and Cui Family Trust | 0 |
Reported balance
After 2026-08-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-10 · Conversion · Disposed 113,435 · Balance 0 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy RongShan, LLC | 0 |
Reported balance
After 2026-08-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-10 · Conversion · Disposed 124,779 · Balance 0 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3: The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 1,067,121 |
Reported balance
Holding disclosure · report date 2026-08-06 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,067,121 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 1,067,121 |
Reported balance
Holding disclosure · report date 2026-08-06 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,067,121 |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
F2: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust.
F3: The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F4: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.
Turning Point Therapeutics, Inc.
Report date June 09, 2020 · Filed June 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 549,471 |
Reported balance
After 2020-06-09 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-06-09 · Sale · Disposed 412 · Balance 549,471 F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2: The weighted average sale price for the transaction reported was $63.80, and the range of prices were between $63.25 and $64.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 547,783 |
Reported balance
After 2020-06-09 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2020-06-09 · Sale · Disposed 1,688 · Balance 547,783 F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3: The weighted average sale price for the transaction reported was $64.82, and the range of prices were between $64.26 and $65.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 543,268 |
Reported balance
After 2020-06-09 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2020-06-09 · Sale · Disposed 4,515 · Balance 543,268 F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4: The weighted average sale price for the transaction reported was $65.80, and the range of prices were between $65.26 and $66.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 540,683 |
Reported balance
After 2020-06-09 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2020-06-09 · Sale · Disposed 2,585 · Balance 540,683 F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5: The weighted average sale price for the transaction reported was $66.60, and the range of prices were between $66.27 and $67.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 540,383 |
Reported balance
After 2020-06-09 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2020-06-09 · Sale · Disposed 300 · Balance 540,383 F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F6: The weighted average sale price for the transaction reported was $67.48, and the range of prices were between $67.34 and $67.915. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | Direct | 1,001,298 |
Reported balance
Holding disclosure · report date 2020-06-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,001,298 |
| Common StockSEC Table I · non-derivative | IndirectBy The Jean Cui 2020 GRAT | 300,000 |
Reported balance
Holding disclosure · report date 2020-06-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 300,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li.
F2: The weighted average sale price for the transaction reported was $63.80, and the range of prices were between $63.25 and $64.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3: The weighted average sale price for the transaction reported was $64.82, and the range of prices were between $64.26 and $65.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4: The weighted average sale price for the transaction reported was $65.80, and the range of prices were between $65.26 and $66.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F5: The weighted average sale price for the transaction reported was $66.60, and the range of prices were between $66.27 and $67.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F6: The weighted average sale price for the transaction reported was $67.48, and the range of prices were between $67.34 and $67.915. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 10, 2026 22:22 UTC | BlossomHill Therapeutics, Inc. BLSM · Entity 5423 | ConversionSeries B Preferred Stock · Derivative | 124,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001772259-26-000005 · form4-08102026_100800.xml · derivative · entry 9 Cui Jingrong Jean · CIK 0001772259 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By RongShan, LLC Disclosed balance after: 0 Underlying: Common Stock · 124,779 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3 · ownership.nature: The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 10, 2026 22:22 UTC | BlossomHill Therapeutics, Inc. BLSM · Entity 5423 | ConversionSeries B Preferred Stock · Derivative | 113,435 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001772259-26-000005 · form4-08102026_100800.xml · derivative · entry 8 Cui Jingrong Jean · CIK 0001772259 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By The Li and Cui Family Trust Disclosed balance after: 0 Underlying: Common Stock · 113,435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. Read SEC document |
| August 10, 2026 Filed Aug 10, 2026 22:22 UTC | BlossomHill Therapeutics, Inc. BLSM · Entity 5423 | ConversionSeries Angel Preferred Stock · Derivative | 1,600,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001772259-26-000005 · form4-08102026_100800.xml · derivative · entry 7 Cui Jingrong Jean · CIK 0001772259 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By The Li and Cui Family Trust Disclosed balance after: 0 Underlying: Common Stock · 1,600,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. Read SEC document |
| August 10, 2026 Filed Aug 10, 2026 22:22 UTC | BlossomHill Therapeutics, Inc. BLSM · Entity 5423 | ConversionCommon Stock | 124,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001772259-26-000005 · form4-08102026_100800.xml · nonDerivative · entry 3 Cui Jingrong Jean · CIK 0001772259 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By RongShan, LLC Disclosed balance after: 124,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3 · ownership.nature: The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 10, 2026 22:22 UTC | BlossomHill Therapeutics, Inc. BLSM · Entity 5423 | ConversionCommon Stock | 113,435 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001772259-26-000005 · form4-08102026_100800.xml · nonDerivative · entry 2 Cui Jingrong Jean · CIK 0001772259 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By The Li and Cui Family Trust Disclosed balance after: 1,714,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. Read SEC document |
| August 10, 2026 Filed Aug 10, 2026 22:22 UTC | BlossomHill Therapeutics, Inc. BLSM · Entity 5423 | ConversionCommon Stock | 1,600,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001772259-26-000005 · form4-08102026_100800.xml · nonDerivative · entry 1 Cui Jingrong Jean · CIK 0001772259 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By The Li and Cui Family Trust Disclosed balance after: 1,600,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 22:22 UTC | BlossomHill Therapeutics, Inc. BLSM · Entity 5423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 676,205 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001772259-26-000005 · form4-08102026_100800.xml · derivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 676,205 Underlying: Common Stock · 676,205 shares Expires 2036-08-05 F4 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 17:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 300 | $67.48 | $20,244.00 |
DisclosureSEC source: 0001209191-20-035621 · doc4.xml · nonDerivative · entry 7 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 540,383 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F6 · price: The weighted average sale price for the transaction reported was $67.48, and the range of prices were between $67.34 and $67.915. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 17:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,585 | $66.60 | $172,161.00 |
DisclosureSEC source: 0001209191-20-035621 · doc4.xml · nonDerivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 540,683 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5 · price: The weighted average sale price for the transaction reported was $66.60, and the range of prices were between $66.27 and $67.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 17:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 4,515 | $65.80 | $297,087.00 |
DisclosureSEC source: 0001209191-20-035621 · doc4.xml · nonDerivative · entry 5 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 543,268 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4 · price: The weighted average sale price for the transaction reported was $65.80, and the range of prices were between $65.26 and $66.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 17:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,688 | $64.82 | $109,416.16 |
DisclosureSEC source: 0001209191-20-035621 · doc4.xml · nonDerivative · entry 4 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 547,783 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3 · price: The weighted average sale price for the transaction reported was $64.82, and the range of prices were between $64.26 and $65.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 17:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 412 | $63.80 | $26,285.60 |
DisclosureSEC source: 0001209191-20-035621 · doc4.xml · nonDerivative · entry 3 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 549,471 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2 · price: The weighted average sale price for the transaction reported was $63.80, and the range of prices were between $63.25 and $64.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 08, 2020 Filed Jun 8, 2020 20:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 5,961 | $63.92 | $381,027.12 |
DisclosureSEC source: 0001209191-20-035149 · doc4.xml · nonDerivative · entry 17 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 549,883 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F16 · price: The weighted average sale price for the transaction reported was $63.92, and the range of prices were between $63.71 and $64.33. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 08, 2020 Filed Jun 8, 2020 20:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 10,667 | $63.36 | $675,861.12 |
DisclosureSEC source: 0001209191-20-035149 · doc4.xml · nonDerivative · entry 16 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 555,844 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F15 · price: The weighted average sale price for the transaction reported was $63.36, and the range of prices were between $62.71 and $63.70. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 08, 2020 Filed Jun 8, 2020 20:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,872 | $62.50 | $117,000.00 |
DisclosureSEC source: 0001209191-20-035149 · doc4.xml · nonDerivative · entry 15 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 566,511 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F14 · price: The weighted average sale price for the transaction reported was $62.50, and the range of prices were between $61.71 and $62.705. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,300 | $65.66 | $85,358.00 |
DisclosureSEC source: 0001209191-20-035149 · doc4.xml · nonDerivative · entry 14 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 568,383 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F13 · price: The weighted average sale price for the transaction reported was $65.66, and the range of prices were between $65.51 and $66.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 4,671 | $65.03 | $303,755.13 |
DisclosureSEC source: 0001209191-20-035149 · doc4.xml · nonDerivative · entry 13 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 569,683 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F12 · price: The weighted average sale price for the transaction reported was $65.03, and the range of prices were between $64.46 and $65.41. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 8,927 | $64.04 | $571,685.08 |
DisclosureSEC source: 0001209191-20-035149 · doc4.xml · nonDerivative · entry 12 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 574,354 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F11 · price: The weighted average sale price for the transaction reported was $64.04, and the range of prices were between $63.46 and $64.45. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,602 | $63.04 | $227,070.08 |
DisclosureSEC source: 0001209191-20-035149 · doc4.xml · nonDerivative · entry 11 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 583,281 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F10 · price: The weighted average sale price for the transaction reported was $63.04, and the range of prices were between $62.445 and $63.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 828 | $69.54 | $57,579.12 |
DisclosureSEC source: 0001209191-20-035149 · doc4.xml · nonDerivative · entry 10 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 586,883 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F9 · price: The weighted average sale price for the transaction reported was $69.54, and the range of prices were between $69.14 and $69.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,072 | $68.62 | $142,180.64 |
DisclosureSEC source: 0001209191-20-035149 · doc4.xml · nonDerivative · entry 9 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 587,711 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F8 · price: The weighted average sale price for the transaction reported was $68.62, and the range of prices were between $68.11 and $69.11. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,800 | $67.52 | $121,536.00 |
DisclosureSEC source: 0001209191-20-035149 · doc4.xml · nonDerivative · entry 8 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 589,783 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F7 · price: The weighted average sale price for the transaction reported was $67.52, and the range of prices were between $67.10 and $67.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 600 | $65.81 | $39,486.00 |
DisclosureSEC source: 0001209191-20-035149 · doc4.xml · nonDerivative · entry 7 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 591,583 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F6 · price: The weighted average sale price for the transaction reported was $65.81, and the range of prices were between $65.38 and $66.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 4,012 | $64.67 | $259,456.04 |
DisclosureSEC source: 0001209191-20-035149 · doc4.xml · nonDerivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 592,183 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5 · price: The weighted average sale price for the transaction reported was $64.67, and the range of prices were between $64.35 and $65.33. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,688 | $63.88 | $235,589.44 |
DisclosureSEC source: 0001209191-20-035149 · doc4.xml · nonDerivative · entry 5 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 596,195 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4 · price: The weighted average sale price for the transaction reported was $63.88, and the range of prices were between $63.35 and $64.34. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,600 | $62.70 | $225,720.00 |
DisclosureSEC source: 0001209191-20-035149 · doc4.xml · nonDerivative · entry 4 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 599,883 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3 · price: The weighted average sale price for the transaction reported was $62.70, and the range of prices were between $62.32 and $63.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,900 | $61.76 | $117,344.00 |
DisclosureSEC source: 0001209191-20-035149 · doc4.xml · nonDerivative · entry 3 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 603,483 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2 · price: The weighted average sale price for the transaction reported was $61.76, and the range of prices were between $61.32 and $62.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 21, 2020 Filed May 21, 2020 19:05 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 100 | $60.34 | $6,034.00 |
DisclosureSEC source: 0001209191-20-031506 · doc4.xml · nonDerivative · entry 11 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 605,383 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. Read SEC document |
| May 21, 2020 Filed May 21, 2020 19:05 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 6,900 | $59.64 | $411,516.00 |
DisclosureSEC source: 0001209191-20-031506 · doc4.xml · nonDerivative · entry 10 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 605,483 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F9 · price: The weighted average sale price for the transaction reported was $59.64, and the range of prices were between $59.13 and $60.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 20, 2020 Filed May 21, 2020 19:05 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,400 | $60.98 | $85,372.00 |
DisclosureSEC source: 0001209191-20-031506 · doc4.xml · nonDerivative · entry 9 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 612,383 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F8 · price: The weighted average sale price for the transaction reported was $60.98, and the range of prices were between $60.60 and $61.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 20, 2020 Filed May 21, 2020 19:05 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 5,100 | $60.03 | $306,153.00 |
DisclosureSEC source: 0001209191-20-031506 · doc4.xml · nonDerivative · entry 8 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 613,783 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F7 · price: The weighted average sale price for the transaction reported was $60.03, and the range of prices were between $59.56 and $60.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 20, 2020 Filed May 21, 2020 19:05 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 500 | $59.04 | $29,520.00 |
DisclosureSEC source: 0001209191-20-031506 · doc4.xml · nonDerivative · entry 7 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 618,883 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F6 · price: The weighted average sale price for the transaction reported was $59.04, and the range of prices were between $58.545 and $59.46. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 19, 2020 Filed May 21, 2020 19:05 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 400 | $58.94 | $23,576.00 |
DisclosureSEC source: 0001209191-20-031506 · doc4.xml · nonDerivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 619,383 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5 · price: The weighted average sale price for the transaction reported was $58.94, and the range of prices were between $58.905 and $58.975. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 19, 2020 Filed May 21, 2020 19:05 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,000 | $58.36 | $175,080.00 |
DisclosureSEC source: 0001209191-20-031506 · doc4.xml · nonDerivative · entry 5 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 619,783 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4 · price: The weighted average sale price for the transaction reported was $58.36, and the range of prices were between $57.89 and $58.845. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 19, 2020 Filed May 21, 2020 19:05 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,400 | $57.44 | $137,856.00 |
DisclosureSEC source: 0001209191-20-031506 · doc4.xml · nonDerivative · entry 4 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 622,783 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3 · price: The weighted average sale price for the transaction reported was $57.44, and the range of prices were between $56.89 and $57.82. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 19, 2020 Filed May 21, 2020 19:05 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,200 | $56.33 | $67,596.00 |
DisclosureSEC source: 0001209191-20-031506 · doc4.xml · nonDerivative · entry 3 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 625,183 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2 · price: The weighted average sale price for the transaction reported was $56.33, and the range of prices were between $55.785 and $56.750. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 100 | $55.16 | $5,516.00 |
DisclosureSEC source: 0001209191-20-028675 · doc4.xml · nonDerivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 626,383 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5 · price: The weighted average sale price for the transaction reported was $55.16, and the range of prices were between $55.16 and $55.16. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 4,750 | $54.49 | $258,827.50 |
DisclosureSEC source: 0001209191-20-028675 · doc4.xml · nonDerivative · entry 5 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 626,483 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4 · price: The weighted average sale price for the transaction reported was $54.49, and the range of prices were between $54.09 and $55.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 5,920 | $53.49 | $316,660.80 |
DisclosureSEC source: 0001209191-20-028675 · doc4.xml · nonDerivative · entry 4 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 631,233 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3 · price: The weighted average sale price for the transaction reported was $53.49, and the range of prices were between $53.09 and $54.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 730 | $52.53 | $38,346.90 |
DisclosureSEC source: 0001209191-20-028675 · doc4.xml · nonDerivative · entry 3 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 637,153 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2 · price: The weighted average sale price for the transaction reported was $52.53, and the range of prices were between $52.05 and $52.975. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 07, 2020 Filed May 7, 2020 18:52 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,330 | $53.70 | $71,421.00 |
DisclosureSEC source: 0001209191-20-027784 · doc4.xml · nonDerivative · entry 10 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 637,883 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F9 · price: The weighted average sale price for the transaction reported was $53.70, and the range of prices were between $53.56 and $54.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 07, 2020 Filed May 7, 2020 18:52 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 11,864 | $53.05 | $629,385.20 |
DisclosureSEC source: 0001209191-20-027784 · doc4.xml · nonDerivative · entry 9 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 639,213 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F8 · price: The weighted average sale price for the transaction reported was $53.05, and the range of prices were between $52.56 and $53.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 07, 2020 Filed May 7, 2020 18:52 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 5,306 | $52.22 | $277,079.32 |
DisclosureSEC source: 0001209191-20-027784 · doc4.xml · nonDerivative · entry 8 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 651,077 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F7 · price: The weighted average sale price for the transaction reported was $52.22, and the range of prices were between $51.56 and $52.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 06, 2020 Filed May 7, 2020 18:52 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 12,428 | $53.13 | $660,299.64 |
DisclosureSEC source: 0001209191-20-027784 · doc4.xml · nonDerivative · entry 7 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 656,383 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F6 · price: The weighted average sale price for the transaction reported was $53.13, and the range of prices were between $52.91 and $53.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 06, 2020 Filed May 7, 2020 18:52 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 6,072 | $52.54 | $319,022.88 |
DisclosureSEC source: 0001209191-20-027784 · doc4.xml · nonDerivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 668,811 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5 · price: The weighted average sale price for the transaction reported was $52.54, and the range of prices were between $51.91 and $52.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 05, 2020 Filed May 7, 2020 18:52 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 5,784 | $54.67 | $316,211.28 |
DisclosureSEC source: 0001209191-20-027784 · doc4.xml · nonDerivative · entry 5 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 674,883 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4 · price: The weighted average sale price for the transaction reported was $54.67, and the range of prices were between $54.39 and $54.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 05, 2020 Filed May 7, 2020 18:52 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 8,718 | $54.04 | $471,120.72 |
DisclosureSEC source: 0001209191-20-027784 · doc4.xml · nonDerivative · entry 4 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 680,667 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3 · price: The weighted average sale price for the transaction reported was $54.04, and the range of prices were between $53.39 and $54.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 05, 2020 Filed May 7, 2020 18:52 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,998 | $53.05 | $212,093.90 |
DisclosureSEC source: 0001209191-20-027784 · doc4.xml · nonDerivative · entry 3 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 689,385 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2 · price: The weighted average sale price for the transaction reported was $53.05, and the range of prices were between $52.380 and $53.360. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 24, 2020 Filed Apr 24, 2020 20:20 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 300 | $51.98 | $15,594.00 |
DisclosureSEC source: 0001209191-20-025731 · doc4.xml · nonDerivative · entry 11 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 693,383 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F10 · price: The weighted average sale price for the transaction reported was $51.98, and the range of prices were between $51.97 and $52.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 24, 2020 Filed Apr 24, 2020 20:20 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,487 | $51.31 | $178,917.97 |
DisclosureSEC source: 0001209191-20-025731 · doc4.xml · nonDerivative · entry 10 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 693,683 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F9 · price: The weighted average sale price for the transaction reported was $51.31, and the range of prices were between $50.93 and $51.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.